Format

Send to

Choose Destination
Cancer Invest. 2016;34(1):39-44. doi: 10.3109/07357907.2015.1088948. Epub 2016 Jan 6.

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.

Author information

1
a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.
2
b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.
3
c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.
4
d Institut National de la Santé et de la Recherche Médicale, U 833 , Paris , France.
5
e Collège de France , Paris , France.
6
f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.
7
g Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle , Paris , France.
8
h OncoNeuroTek , Paris , France.

Erratum in

Abstract

Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.

KEYWORDS:

Ang2; Glioblastoma; bevacizumab; plasma biomarkers

PMID:
26735326
DOI:
10.3109/07357907.2015.1088948
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center